“HTGF is very supportive and easy to work with. They foster a collaborative environment and respond very fast to any request.”
David Neale Founder and CEO of Argá Medtech
Spotlight Life Sciences & Chemistry
8 of 500 Companies
2022
EEDEN
North Rhine-Westphalia
Recycling
EEDEN starts upcycling – turning textile waste into valuable ressources for new fibres. The Company developed a chemical upcycling process for textile waste, recovering its resources. In this way, new, …
Argá Medtech, developing the next generation Cardiac Ablation system for the treatment of Atrial Fibrillation and other arrhythmias. A safer, simpler, faster and more effective procedure for the benefit of …
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …
Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device …
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …
MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis B and delta. The drug has been approved by the EMA for the treatment …
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …
Germany is one of the global leaders in life science research. We invest in disruptive technologies and visionaries not only to further innovation, but also to actively shape the market.
MedTech and Digital Health
Societal challenges such as demographic change, the shortage of skilled workers or complex diseases demand visionary answers. Together, we transform these into market-relevant solutions.
Chemistry
How do we feed a growing world population in the future, how do we counter the effects of climate change? We believe in the answers provided by science – and we know the challenges of lab-to-market startups from our own experience.
We see the potential for real innovation before anyone else does – with a deep understanding of the market and excellent connections to research, institutes and universities. We are the door opener that your start-up needs in the financing round to revolutionise the market.
We invest first.
open/close
Early-stage investments are at the heart of our business: we take early ristks on to ensure that your solution gets market ready.
Bridge-building: from science to venture.
open/close
As a diverse team drawn from science, medicine and entrepreneurs, we are familiar with the challenges you face – including those that await you tomorrow.
Our network is your superpower.
open/close
With our large network and over 45 companies invested in the fund, you will find the right partners to drive your business forward.
770 Ventures, one HTGF family.
open/close
Talents are your resource for success, collaborations your lever for transformation. Join the family – and grow beyond yourself.
It’s you who can change the world.
We have helped some of Germany’s most innovative companies get off the ground. We are the right partner for you, too, if…
you are R&D-based, but your business network needs to be expanded.
you have an innovative solution, technology or patent, but your lab-to-market strategy needs to be built.
your company is facing regulatory hurdles that overwhelm your team resources.
you are in an early phase and need a strong consortium for the challenging development.